# Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma

> **NCT00651443** · PHASE1 · TERMINATED · sponsor: **Biogen** · enrollment: 20 (estimated)

## Conditions studied

- Lymphoma, Non-Hodgkin's

## Interventions

- **DRUG:** Galiximab

## Key facts

- **NCT ID:** NCT00651443
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-08
- **Primary completion:** 2010-11
- **Final completion:** 2010-12
- **Target enrollment:** 20 (ESTIMATED)
- **Why stopped:** A company's strategic decision to focus on areas whereit believes it can be competitive and decided to exit Oncology
- **Last updated:** 2011-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00651443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00651443, "Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00651443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*